depression

Home>Tag:depression
Sep 9 2024

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

By |2024-09-08T17:19:55-04:00September 9th, 2024|Featured, Investor News, Press Releases|0 Comments

Early Pilot Study Data from Veteran Volunteers is Compelling.  Part B. Jackson Center, PA September 5, 2024 – Halberd Corporation (OTC-PINK: "HALB”) We hope you have had an opportunity to check out this Press release’s Part A. This Part B supplements that release of a few days ago. As always reach out to us if ...

May 22 2024

Halberd/Athena GTX Research Promises a Much Brighter Future

By |2024-05-21T16:43:28-04:00May 22nd, 2024|Featured, Investor News, News, Press Releases, Technology|0 Comments

Walt Disney once said, “All our dreams can come true if we have the courage to pursue them”. Jackson Center, PA May 22, 2024 – Halberd Corporation (OTC-PINK: "HALB”) in cooperation with Athena GTX, Inc is standing at the threshold of some major advancements to treat the issues facing not only our military but people ...

Apr 4 2024

Halberd’s Patented Drug, LDN+, the Subject of a Limited Clinical Trial under an Innovative Four-company Cooperative Research and Development (CRADA) Contract.

By |2024-04-04T17:47:08-04:00April 4th, 2024|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, April 4, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just ...

Go to Top